NASDAQ:XLRN - Acceleron Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$46.58 +0.28 (+0.60 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$46.30
Today's Range$45.38 - $46.75
52-Week Range$30.74 - $50.00
Volume469,700 shs
Average Volume374,402 shs
Market Capitalization$2.13 billion
P/E Ratio-17.38
Dividend YieldN/A
Acceleron Pharma logoAcceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity RatioN/A
Current Ratio23.21
Quick Ratio23.21


Trailing P/E Ratio-17.38
Forward P/E Ratio-19.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.48 million
Price / Sales158.19
Cash FlowN/A
Price / CashN/A
Book Value$8.07 per share
Price / Book5.77


EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-839.98%
Return on Equity-34.52%
Return on Assets-32.40%


Outstanding Shares45,780,000
Market Cap$2,128.55

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.64) by $0.06. The biopharmaceutical company earned $3.23 million during the quarter, compared to analyst estimates of $3.77 million. Acceleron Pharma had a negative net margin of 839.98% and a negative return on equity of 34.52%. The business's revenue was down 12.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.66) EPS. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

13 equities research analysts have issued 12-month price objectives for Acceleron Pharma's shares. Their predictions range from $32.00 to $74.00. On average, they expect Acceleron Pharma's stock price to reach $51.60 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price. View Analyst Ratings for Acceleron Pharma.

What is the consensus analysts' recommendation for Acceleron Pharma?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. Cann analysts commented, "While we have not modeled ACE-083 into our outlook for Track designation received in May 2018 has the potential to move the timeline for Status announced today has the potential to positively impact pricing and exclusivity of ACE-083 in the FSHD setting. Based on this development and recently released positive results for ACE-083, we believe this program will continue to advance and will likely become a marketed drug. ACE-083 could provide upside to our outlook." (7/12/2018)
  • 2. HC Wainwright analysts commented, "Preliminary ACE-083 Phase 2 Data Demonstrates Serious Gains in FSHD; Part 2 Current Underway Data demonstrates dose-dependent increases in total muscle volume. This morning, Acceleron Pharma announced preliminary results from the ongoing Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) from the 150 and 200mg arms at the American Academy of Neurology (AAN) 70th Annual Meeting, which is being held in Los Angeles. ACE-083 demonstrated dose-dependent increases in total muscle volume in both the Tibalis Anterior (TA) and Biceps Brachii (BB) muscle cohorts, with a 15-20% increase observed at the higher dose level. In addition, a decrease in fat fraction was observed in both cohorts, however, it was more notable in the TA cohort. With regard to safety, ACE-083 was safe and generally well-tolerated in subjects for up to three months, which included five doses." (4/26/2018)
  • 3. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
  • Mr. Kevin F. McLaughlin, CFO, Sr. VP & Treasurer (Age 62)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 58)
  • Dr. Matthew L. Sherman, Chief Medical Officer & Exec. VP (Age 62)

Has Acceleron Pharma been receiving favorable news coverage?

Media stories about XLRN stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acceleron Pharma earned a daily sentiment score of 0.15 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Neville Rodie & Shaw Inc. (0.09%), Verde Servicos Internacionais S.A. (0.02%), Campbell & CO Investment Adviser LLC (0.02%) and Amalgamated Bank (0.01%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Which major investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A.. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.

Which major investors are buying Acceleron Pharma stock?

XLRN stock was bought by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Campbell & CO Investment Adviser LLC and Amalgamated Bank. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $46.58.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $2.13 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]

MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  356 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.